Table 3 Characteristics of patients shifted toward to high category in Ca level during the 3-month intervals
M-L and M-M groups | M-H group | SMD | |
|---|---|---|---|
Demographics | |||
Age, years | 62.0 ± 20.2 | 60.8 ± 19.6 | 0.06 |
Sex, female, % | 36.5 | 40.4 | 0.15 |
Body mass index, kg/m2 | 21.5 ± 5.7 | 21.4 ± 5.6 | 0.01 |
Cause of end-stage kidney disease, % | |||
Glomerulonephritis | 39.3 | 46.6 | |
Diabetic nephropathy | 29.4 | 22.6 | 0.17 |
Others | 31.4 | 30.8 | |
Comorbidities, % | |||
Diabetes mellitus | 36.9 | 28.5 | 0.18 |
Cardiovascular diseases | 58.6 | 57.8 | 0.02 |
Lung diseases | 7.2 | 7.0 | 0.01 |
Liver diseases | 12.8 | 13.8 | 0.03 |
Malignancies | 4.7 | 4.1 | 0.03 |
Dialysis | |||
Log duration of dialysis, years | 0.7 ± 0.7 | 0.7 ± 12.6 | 0.14 |
Kt/V, single pool | 1.4 ± 0.5 | 1.5 ± 0.5 | 0.07 |
Dialysate calcium, mEq/L | 2.7 ± 0.4 | 2.8 ± 0.4 | 0.03 |
Laboratory data | |||
Albumin, g/dL | 3.7 ± 0.5 | 3.7 ± 0.5 | 0.00 |
Hemoglobin, g/dL | 10.5 ± 1.8 | 10.6 ± 1.8 | 0.05 |
MBD-related characteristics | |||
Serum parameters | |||
P, mg/dL | 5.4 ± 2.2 | 5.6 ± 2.2 | 0.09 |
Log iPTH, pg/mL | 2.3 ± 0.5 | 2.3 ± 0.5 | 0.05 |
History of parathyroidectomy, % | 4.4 | 6.2 | 0.08 |
Prescription of MBD-related agents, % | |||
VDRAs | 79.8 | 86.4 | 0.22 |
Intravenous | 45.3 | 55.4 | |
Oral | 34.5 | 31.0 | |
Phosphate binders | 85.8 | 89.5 | 0.16 |
Both | 26.4 | 31.4 | |
Non–Ca-based | 15.0 | 17.3 | |
Ca-based | 44.4 | 40.7 | |
Cinacalcet | 19.3 | 28.2 | 0.21 |